Guest blog by Dave Mead, Director of Business Development, Isogenica Limited
I recently joined One Nucleus ’ BioWednesday panel to debate whether using Government R&D incentives are worth it.
Blog
Guest blog by Grace Gregory, Student, University of Manchester
1 in 4 people in England will experience a mental health problem of some kind each year (The Adult Psychiatric Morbidity Survey, 2007). The more we talk about mental health the more we break down the stigma and create a safe place for people to speak out about how they are feeling. Mental health problems can affect individuals very differently and be completely invisible to others.
Tony Jones, CEO & Jasmin Bannister, Events & Communications Administrator - One Nucleus
“Good company in a journey makes the way seem shorter”
Hanna Beaumont FIRM, Director, Science Technology, Partners&
Safety in the lab, working from home, employment law, contract disputes, Covid... company directors are now exposed to unprecedented liability for actions and decisions they make on behalf of their business. This means direct exposure of the personal assets of your board members and key decision makers – including NEDs.
Tony Jones, Chief Executive Officer, One Nucleus
Tony Jones, Chief Executive Officer, One Nucleus
As always, it is a privileged part of the month where I get to be in contact with the One Nucleus network by welcoming you to our eNews.
Guest blog by Charles Richmond, F-Institute
Guest blog by Joanne Ward, Chief Operations Officer, NF2 Biosolutions UK
I haven’t written a blog before but have shared my story in case it helps others along on their journey. They say sharing your story of how you overcome things is someone else’s survival guide!
What is a cytokine storm?
Cytokine Release Syndrome (CRS), otherwise known as cytokine storm, is a systemic inflammatory response caused by complications due to disease, infection or an adverse effect of biologic therapy. The clinical symptoms of a cytokine storm are massive release of a potent cocktail of pro-inflammatory cytokines into the general circulatory system, leading to severe multi-organ damage, failure or potentially death. This is an extremely unwanted immunotoxicological side effect in drug development.